Jul 25
|
Top Midday Stories: US Advance Q2 GDP Rises; Initial Jobless Claims Drop; Ford Earnings Fall; TotalEnergies' Lower Results; AbbVie Raises Guidance; IBM, ServiceNow Report Higher Results
|
Jul 25
|
New Drug Sales Lift AbbVie Stock
|
Jul 25
|
AbbVie (ABBV) Beats on Q2 Earnings & Sales, Ups '24 EPS View
|
Jun 19
|
Why AbbVie (ABBV) is a Great Dividend Stock Right Now
|
Jun 19
|
Here's Why AbbVie (ABBV) is a Strong Momentum Stock
|
Jun 19
|
AbbVie's (ABBV) Skyrizi Gets FDA Nod for Ulcerative Colitis
|
Jun 19
|
2 Super Smart Dividend Stocks to Buy With $10,000 Right Now
|
Jun 19
|
AbbVie’s SKYRIZI gains US FDA approval for ulcerative colitis
|
Jun 18
|
U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie's Portfolio Across Inflammatory Bowel Disease
|
Jun 18
|
AbbVie (ABBV) Exceeds Market Returns: Some Facts to Consider
|
Jun 18
|
Intra-Cellular Therapies edges closer to FDA win for Caplyta in depression
|
Jun 18
|
Mustang (MBIO) Soars 477% on Data From Rare Blood Cancer Study
|
Jun 18
|
Humira: the highs and lows of the world’s best-selling drug
|
Jun 16
|
2 Dividend Stocks That Could Pay You for Life
|
Jun 14
|
AbbVie Recommends Shareholders Reject Tutanota's "Mini-Tender" Offer
|
Jun 14
|
Pharma Stock Roundup: FDA Panel Endorses LLY's Donanemab, PFE's DMD Therapy Study Fails
|
Jun 14
|
AbbVie (ABBV) Buys Global Rights to Novel IBD Candidate
|
Jun 14
|
AbbVie joins in latest gastrointestinal drug chase
|
Jun 14
|
AbbVie and FutureGen link on inflammatory bowel disease
|
Jun 13
|
Here's How Many Shares Of AbbVie You Would Need To Earn $500 Per Month In Dividends
|